A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and treatment accessibility, with clinicians helping patients navigate financial ...
An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...
Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...
The European Medicines Agency (EMA) has recommended granting marketing authorization for rilzabrutinib (Wayrilz, Sanofi) to treat immune thrombocytopenia (ITP) in adults who are refractory to other ...
Have you ever felt like your body isn’t quite playing by the rules? Living with Immune Thrombocytopenia (ITP) can sometimes feel like an unpredictable journey, with fluctuating platelet levels and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results